Skip to main content

Table 2 Cox regression analysis for PFS predicting

From: Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

Characteristics Univariate analysis Multivariate analysis
HR (95 % CI) P HR (95 % CI) P
Age 0.982 (0.951–1.014) 0.2716 0.978 (0.943–1.015) 0.2371
ER and/or PR: Positive vs. Negative 1.854 (1.015–3.454) 0.0467 1.977 (0.928–4.39) 0.0841
Pathology type: ILC vs. IDC 3.911 (0.215–19.691) 0.1891 3.691 (0.169–31.259) 0.2832
Pathology type: Other vs. IDC 0.936 (0.28–2.336) 0.8995 1.49 (0.395–4.625) 0.5148
CTC Number: ≥ 5 vs. < 5 1.141 (0.631–2.064) 0.6606 1.321 (0.686–2.581) 0.4068
CTC Her2: Positive vs. Negative 0.321 (0.156–0.62) 0.0011 0.383 (0.166–0.831) 0.019
No. of Metastasis: ≥ 2 vs. = 1 0.968 (0.441–2.551) 0.9406 0.746 (0.296–2.155) 0.5566
Metastatic sites: Visceral vs. Non-visceral 0.812 (0.431–1.637) 0.5357 0.591 (0.276–1.356) 0.1907
Systemic therapy line: ≥ 2 vs. = 1 2.309 (0.84–9.543) 0.1619 2.041 (0.626–9.313) 0.2856
Treatment option: L + Che vs. T + Che 0.859 (0.446–1.789) 0.6639 0.911 (0.411–1.863) 0.8063
  1. Abbreviation: IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, L lapatinib, T trastuzumab, Che chemotherapy, HR hazard rate